HC Wainwright Issues Positive Estimate for TPST Earnings

Tempest Therapeutics, Inc. (NASDAQ:TPST) – Investment analysts at HC Wainwright lifted their Q3 2026 earnings per share (EPS) estimates for shares of Tempest Therapeutics in a research report issued to clients and investors on Thursday, September 24th. HC Wainwright analyst J. Pantginis now expects that the company will post earnings per share of ($0.32) for the quarter, up from their previous estimate of ($0.35). The consensus estimate for Tempest Therapeutics’ current full-year earnings is ($0.83) per share. HC Wainwright also issued estimates for Tempest Therapeutics’ Q4 2026 earnings at ($0.29) EPS, FY2026 earnings at ($0.83) EPS and FY2027 earnings at ($0.90) EPS.

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Tempest Therapeutics in a report on Monday, July 13th. One equities research analyst has rated the stock with a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Reduce”.

Tempest Therapeutics Trading Up 0.3%

TPST stock opened at $0.83 on Monday. The firm has a 50-day moving average price of $0.98 and a 200-day moving average price of $1.38. Tempest Therapeutics has a 12 month low of $0.74 and a 12 month high of $12.23. The stock has a market capitalization of $13.75 million, a P/E ratio of -0.19 and a beta of -1.68.

Tempest Therapeutics (NASDAQ:TPST) last released its earnings results on Thursday, August 13th. The company reported ($0.34) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.30) by ($0.04).

Institutional Investors Weigh In On Tempest Therapeutics

An institutional investor recently bought a new position in Tempest Therapeutics stock. Squarepoint Ops LLC acquired a new position in shares of Tempest Therapeutics, Inc. (NASDAQ:TPST) during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 30,900 shares of the company’s stock, valued at approximately $34,000. Squarepoint Ops LLC owned about 0.19% of Tempest Therapeutics as of its most recent SEC filing. Institutional investors and hedge funds own 22.52% of the company’s stock.

Tempest Therapeutics Company Profile

Tempest Therapeutics, Inc is a clinical-stage biotechnology company focused on developing small-molecule medicines for cancer. Its research combines tumor-targeted approaches with immune-system modulation, with the goal of addressing both cancer-cell biology and the tumor microenvironment.

The company’s pipeline has included TPST-1120, an oral, selective antagonist of peroxisome proliferator-activated receptor alpha (PPAR?). The program is being investigated for advanced solid tumors, including hepatocellular carcinoma, as a monotherapy and in combination with other cancer treatments.